Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Asset Writedowns and Impairment: 2010-2016

Historic Asset Writedowns and Impairment for Capricor Therapeutics (CAPR) over the last 2 years, with Dec 2016 value amounting to $1.5 million.

  • Capricor Therapeutics' Asset Writedowns and Impairment changed negligibly% to $106,830 in Q3 2013 from the same period last year, while for Sep 2013 it was $427,320, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.5 million for FY2016, which is N/A change from last year.
  • As of FY2016, Capricor Therapeutics' Asset Writedowns and Impairment stood at $1.5 million, which was up 1,304.10% from $106,830 recorded in FY2010.
  • In the past 5 years, Capricor Therapeutics' Asset Writedowns and Impairment registered a high of $1.5 million during FY2016, and its lowest value of $1.5 million during FY2016.
  • Its 1-year average for Asset Writedowns and Impairment is $1.5 million, with a median of $1.5 million in 2016.